<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02038153</url>
  </required_header>
  <id_info>
    <org_study_id>13-08-148</org_study_id>
    <secondary_id>NCI-2013-02493</secondary_id>
    <secondary_id>13-08-148</secondary_id>
    <secondary_id>P30CA013330</secondary_id>
    <nct_id>NCT02038153</nct_id>
  </id_info>
  <brief_title>Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant</brief_title>
  <official_title>A Phase I/II Study of Lenalidomide Maintenance After Autologous Stem Cell Transplant for Elderly Patients With Acute Myeloid Leukemia (AML)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the side effects and best dose of lenalidomide and how well it
      works in treating older patients with acute myeloid leukemia (AML) who have undergone stem
      cell transplant. Biological therapies, such as lenalidomide, may stimulate the immune system
      in different ways and stop cancer cells from growing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the safety and efficacy of maintenance lenalidomide post autologous
      peripheral blood stem cell transplantation (PBSCT) for elderly patients with AML (AML).

      SECONDARY OBJECTIVES:

      I. To define maximum tolerated dose (MTD) and establish therapeutic dose level (TDL) of
      lenalidomide given post autologous transplant for AML.

      II. To determine the progression free survival for patients treated with this approach.

      III. To determine the overall survival for patients treated with this approach. IV. To
      determine the role of residual AML stem cells on efficacy of lenalidomide maintenance after
      autologous PBSCT.

      OUTLINE: This is a phase I, dose-escalation study followed by a phase II study.

      Patients receive lenalidomide orally (PO) once daily (QD) on days 1-21. Courses repeat 4
      weeks in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up at 30 days and then every 6
      months thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low accrual
  </why_stopped>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse Free Survival Rate</measure>
    <time_frame>initial 2 years after treatment begins</time_frame>
    <description>The Relapse free survival rate is defined as the Leukemia free survival rate during the first two years after and during the initiation of treatment . The observed relapse free survival rate will be calculated along with its 95% confidence interval. A one sample test on proportion will be used to detect if the relapse free survival rate with lenalidomide is significantly higher than that without the treatment (relapse rate is expected to be &gt; 95%).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From transplant until death of any cause, assessed up to 5 years</time_frame>
    <description>Kaplan-Meier analysis will be conducted.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome</condition>
  <condition>Adult Acute Myeloid Leukemia in Remission</condition>
  <arm_group>
    <arm_group_label>Treatment (lenalidomide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive lenalidomide PO QD on days 1-21. Courses repeat 4 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (lenalidomide)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (lenalidomide)</arm_group_label>
    <other_name>CC-5013</other_name>
    <other_name>CC5013</other_name>
    <other_name>CDC 501</other_name>
    <other_name>Revlimid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have a confirmed diagnosis of non-M3 AML; antecedent myelodysplastic
             syndrome (MDS) is acceptable

          -  Post autologous stem cell transplant bone marrow biopsy core that is consistent with
             morphologic remission

          -  Must have received induction and consolidation chemotherapy, and autologous stem cell
             transplant for AML

          -  Life expectancy of greater than 12 months

          -  Karnofsky performance status 70 or greater

          -  Leukocytes &gt;= 2,000/mcL

          -  Absolute neutrophil count &gt;= 1,000/mcL

          -  Platelets &gt;= 75,000/mcL

          -  Total bilirubin =&lt; 4 X institutional upper limit of normal unless 2nd to Gilbert's
             disease

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =&lt; 4 X
             institutional upper limit of normal

          -  Creatinine &lt; 1.5 X institutional upper limit of normal OR creatinine clearance &gt;= 30
             mL/min/1.73 m^2 for patients with creatinine levels above institutional normal

          -  Able to take aspirin, or warfarin, or low molecular weight heparin as prophylactic
             anticoagulation

          -  Ability to understand and the willingness to sign a written informed consent document

          -  Must be registered into the mandatory RevAssist® program and be willing and able to
             comply with the requirement of RevAssist®

        Exclusion Criteria:

          -  Patient received chemotherapy or radiotherapy within 2 weeks prior to entering the
             study or has not recovered from adverse events due to agents administered more than 4
             weeks earlier

          -  Patient received another investigational agent after post autologous stem cell
             transplant

          -  Patient who will be receiving another investigational product during the study

          -  Patient who is growth factor or transfusion dependent

          -  Patient has central nervous system leukemia

          -  History of allergic reactions attributed to thalidomide or lenalidomide

          -  History of erythema nodosum, characterized by a desquamating rash while taking
             thalidomide or similar drugs

          -  Prior history of metastatic malignancy

          -  Uncontrolled illness including, but not limited to ongoing or active infection,
             unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations
             that would limit compliance with study requirements; patients must not have suffered
             recent (&lt; 6 months) myocardial infarction, unstable angina, uncontrolled hypertension,
             or difficult to control cardiac arrhythmias

          -  Evidence of uncontrolled congestive heart failure

          -  Active hepatitis B as defined by hepatitis B surface antigen positivity, unless able
             to start dual anti-hepatitis B (HepB) therapy, or already on dual anti-HepB therapy

          -  Patients who are positive for hepatitis B core antibody, but negative for the
             hepatitis B surface antigen, should be on lamivudine 100 mg daily until at least 3
             months post-transplant

          -  Patient is positive for human immunodeficiency virus (HIV) or human T-cell
             lymphotropic virus-1 (HTLV-1)

          -  Women of childbearing potential (defined as a sexually mature woman who has not
             undergone a hysterectomy or who has had menses at any time in the preceding 24
             consecutive months)

          -  Men who did not agree not to father a child and who refused to use a latex condom
             during any sexual contact with women of childbearing potential while taking
             lenalidomide and for 4 weeks after therapy is stopped, even if they have undergone a
             successful vasectomy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ira Braunschweig</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center - Moses Campus</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467-2490</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center of Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 15, 2014</study_first_submitted>
  <study_first_submitted_qc>January 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2014</study_first_posted>
  <results_first_submitted>March 12, 2020</results_first_submitted>
  <results_first_submitted_qc>May 4, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 14, 2020</results_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Albert Einstein College of Medicine</investigator_affiliation>
    <investigator_full_name>Ira Braunschweig</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 3, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT02038153/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 26, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT02038153/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Lenalidomide)</title>
          <description>Patients receive lenalidomide PO QD on days 1-21. Courses repeat 4 weeks in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Lenalidomide: Given PO</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Lenalidomide)</title>
          <description>Patients receive lenalidomide PO QD on days 1-21. Courses repeat 4 weeks in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Lenalidomide: Given PO</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Relapse Free Survival Rate</title>
        <description>The Relapse free survival rate is defined as the Leukemia free survival rate during the first two years after and during the initiation of treatment . The observed relapse free survival rate will be calculated along with its 95% confidence interval. A one sample test on proportion will be used to detect if the relapse free survival rate with lenalidomide is significantly higher than that without the treatment (relapse rate is expected to be &gt; 95%).</description>
        <time_frame>initial 2 years after treatment begins</time_frame>
        <population>Study terminated because of low accrual. No analysis done</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Lenalidomide)</title>
            <description>Patients receive lenalidomide PO QD on days 1-21. Courses repeat 4 weeks in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Lenalidomide: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Relapse Free Survival Rate</title>
          <description>The Relapse free survival rate is defined as the Leukemia free survival rate during the first two years after and during the initiation of treatment . The observed relapse free survival rate will be calculated along with its 95% confidence interval. A one sample test on proportion will be used to detect if the relapse free survival rate with lenalidomide is significantly higher than that without the treatment (relapse rate is expected to be &gt; 95%).</description>
          <population>Study terminated because of low accrual. No analysis done</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Kaplan-Meier analysis will be conducted.</description>
        <time_frame>From transplant until death of any cause, assessed up to 5 years</time_frame>
        <population>Study terminated because of low accrual. No analysis done</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Lenalidomide)</title>
            <description>Patients receive lenalidomide PO QD on days 1-21. Courses repeat 4 weeks in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Lenalidomide: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Kaplan-Meier analysis will be conducted.</description>
          <population>Study terminated because of low accrual. No analysis done</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Lenalidomide)</title>
          <description>Patients receive lenalidomide PO QD on days 1-21. Courses repeat 4 weeks in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Lenalidomide: Given PO</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ira Braunschweig</name_or_title>
      <organization>Montefiore</organization>
      <phone>718 920-4826</phone>
      <email>ibraunsc@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

